Is Zymeworks Inc. (ZYME) Stock an Undervalued Biotech Opportunity With Oncology Growth Ahead?

We recently compiled a list of the 10 Best Biotech Stocks to Buy According to Analysts. Zymeworks Inc. (NASDAQ:ZYME) is one of the best biotech stocks on this list.

TheFly reported on June 9 that Truist Securities initiated coverage of ZYME with a Buy rating and a $28 price target, down from $40. The firm highlighted ZYME as a balanced investment opportunity, supported by its royalty-based business model and expanding oncology pipeline that could provide long-term growth potential. Truist also pointed to pipeline assets, including Pasritamig in metastatic castration-resistant prostate cancer, as potential contributors due to upcoming clinical milestones.

Is Zymeworks Inc. (ZYME) Stock an Undervalued Biotech Opportunity With Oncology Growth Ahead?

Separately, on June 14, Zymeworks Inc. (NASDAQ:ZYME) presented updated clinical findings from the dose-escalation phase of its ongoing Phase 1 trial assessing ZW191, an antibody-drug conjugate targeting folate receptor alpha. The data were presented at the European Society for Medical Oncology (ESMO) Gynaecological Cancers Congress 2026. Results showed encouraging anti-tumor activity in platinum-resistant ovarian cancer patients across different FRalpha expression levels. ZW191 achieved a confirmed objective response rate of 78.6% in FRalpha-positive patients and 47.4% in FRalpha-negative patients across evaluated dose levels. Median duration of response had not yet been reached, while median progression-free survival was 7.6 months across ovarian and endometrial cancer groups. Dose optimization enrollment was completed, with tolerability results supporting further clinical development.

Zymeworks Inc. (NASDAQ:ZYME) is a clinical-stage biotechnology company developing next-generation cancer therapies, including multispecific antibodies and antibody-drug conjugates (ADCs).

While we acknowledge the risk and potential of ZYME as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than ZYME and that has 10,000% upside potential, check out our report about this cheapest AI stock.

READ NEXT: 33 Stocks That Should Double in 3 Years and 15 Stocks That Will Make You Rich in 10 Years 

Disclosure: None. Follow Insider Monkey on Google News.

1281292 - 11759070 - 1